FACT II Acquisition 주식 가격. FACT - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

가격

9.97

매수가

9.81

매도가

10.15

거래량

3,036

9.97 일간 변동폭 9.98

9.85 52주 범위 27.01

전일 종가

9.97

개장가

9.98

최근 거래 시간

100

9.97

마지막 거래 시간

06:00:00

평균 볼륨(3m)

51,290

재정 규모

US$ 30,284

VWAP

9.975

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation PR Newswire INCLINE VILLAGE, Nev., March 24 INCLINE VILLAGE, Nev., March...

Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Facet Biotech Corporation by Abbott Laboratories

Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of...

Kendall Law Group Investigates Facet Biotech Corporation Merger for Shareholders

Kendall Law Group, a national securities litigation firm is investigating Facet Biotech Corporation (NASDAQ: FACT) for...

Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Facet Biotech Corporation

Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Facet...

Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of Facet Biotech Corporation - FACT

Levi & Korsinsky is investigating the Board of Directors of Facet Biotech Corporation (“Facet Biotech” or the “Company”...

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9 /PRNewswire-FirstCall/ -- Abbott and Facet Biotech Corporation announced today a definitive...

Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors

SAN FRANCISCO, Jan. 11 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage cancer biotherapeutics company...

Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting

SEATTLE and REDWOOD CITY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) and Facet Biotech Corp...

Facet Biotech & Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multip...

Facet Biotech Corporation (Nasdaq: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	9.97	9.99	9.96	6346	9.97142294	CS
4	0.04	0.402819738167	9.93	10.0507	9.915	48713	9.95204373	CS
12	-17.04	-63.0877452795	27.01	27.01	9.85	51290	9.91124417	CS
26	-17.04	-63.0877452795	27.01	27.01	9.85	22157	9.91124417	CS
52	-17.04	-63.0877452795	27.01	27.01	9.85	11079	9.91124417	CS
156	-17.04	-63.0877452795	27.01	27.01	9.85	3683	9.91124417	CS
260	-17.04	-63.0877452795	27.01	27.01	9.85	2513	9.91124417	CS

FACT - Frequently Asked Questions (FAQ)

What is the current FACT II Acquisition share price?

The current share price of FACT II Acquisition is US$ 9.97

What is the 1 year trading range for FACT II Acquisition share price?

FACT II Acquisition has traded in the range of US$ 9.85 to US$ 27.01 during the past year

가장 활성
% 상승자
% 패자

기호	가격	볼륨
ULYUrgent ly Inc	US$ 0.8839 (110.45%)	4.17M
CPOPPop Culture Group Company Ltd	US$ 1.32 (90.75%)	8.16M
BLMZBloomZ Inc	US$ 0.485 (34.80%)	6.44M
NIXXNixxy Inc	US$ 2.03 (28.48%)	7.4M
BBLGBone Biologics Corporation	US$ 1.1598 (23.30%)	550.21k
SYTASiyata Mobile Inc	US$ 3.03 (-27.34%)	431.4k
SPGCSacks Parente Golf Inc	US$ 0.5531 (-24.45%)	1.34M
PITAHeramba Electric PLC	US$ 0.5508 (-20.00%)	1.43M
ONVOOrganovo Holdings Inc	US$ 0.691 (-18.71%)	2.15M
DMRCDigimarc Corporation	US$ 22.50 (-16.79%)	21.69k
NVDANVIDIA Corporation	US$ 132.60 (1.01%)	33.99M
CPOPPop Culture Group Company Ltd	US$ 1.32 (90.75%)	8.16M
NIXXNixxy Inc	US$ 2.03 (28.48%)	7.4M
BLMZBloomZ Inc	US$ 0.485 (34.80%)	6.44M
CLEUChina Liberal Education Holdings Ltd	US$ 0.0635 (-14.54%)	5.99M

게시물을 찾을 수 없습니다

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

FACT II Acquisition Corporation (FACT)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

FACT 최신 뉴스

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation

Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Facet Biotech Corporation by Abbott Laboratories

Kendall Law Group Investigates Facet Biotech Corporation Merger for Shareholders

Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Facet Biotech Corporation

Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of Facet Biotech Corporation - FACT

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors

Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting

Facet Biotech & Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multip...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

FACT - Frequently Asked Questions (FAQ)

이동자

FACT Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

FACT II Acquisition Corporation (FACT) 시세

FACT II Acquisition Corporation (FACT)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

FACT 최신 뉴스

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation

Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Facet Biotech Corporation by Abbott Laboratories

Kendall Law Group Investigates Facet Biotech Corporation Merger for Shareholders

Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Facet Biotech Corporation

Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of Facet Biotech Corporation - FACT

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors

Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting

Facet Biotech & Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multip...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

FACT - Frequently Asked Questions (FAQ)

이동자

FACT Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거